CAT-2003: Preliminary Phase I data

Preliminary data from a 2-part, double-blind, placebo-controlled, U.S. Phase I trial showed that oral CAT-2003 was well tolerated with no serious adverse events reported. Catabasis said CAT-2003 also ...